iTeos Therapeutics SA
9Patents
9Active
9Granted
45Portfolio score
Filing activity: Feb 11, 2015 → Mar 14, 2019
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10329349B2 | Anti-TIGIT antibodies | Emerging Cross-Sectional Technologies | 5 | Active |
| US9873690B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | Chemistry; Metallurgy | 1 | Active |
| US10398679B2 | Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors | Chemistry; Metallurgy | 1 | Active |
| US9949951B2 | Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors | Chemistry; Metallurgy | 1 | Active |
| US9603836B2 | Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors | Chemistry; Metallurgy | 1 | Active |
| US10995101B2 | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers | Chemistry; Metallurgy | 0 | Active |
| US9758505B2 | 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use | Chemistry; Metallurgy | 0 | Active |
| US10544095B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | Chemistry; Metallurgy | 0 | Active |
| US10945994B2 | Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.